Argenx
ARGX
#402
Rank
A$87.94 B
Marketcap
A$1,399
Share price
-1.73%
Change (1 day)
-1.71%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2026 (TTM): A$33.08

According to Argenx 's latest financial reports the company's current EPS (TTM) is A$33.78. In 2025 the company made an earnings per share (EPS) of A$31.85 an increase over its 2024 EPS that were of A$21.03.

EPS history for Argenx from 2011 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$33.083.88%
2025A$31.8551.44%
2024A$21.03-369.77%
2023A-$7.80-60.46%
2022A-$19.7263.33%
2021A-$12.07-40.37%
2020A-$20.24183.47%
2019A-$7.14123.09%
2018A-$3.2054.93%
2017A-$2.0714.07%
2016A-$1.8113.05%
2015A-$1.60-36.34%
2014A-$2.52209.04%
2013A-$0.81-33.99%
2012A-$1.23185.59%
2011A-$0.43